Retatrutide carries a unique side effect, dysesthesia (tingling or burning sensations), reported in roughly 20.9% of participants at the 12 mg dose, not observed with tirzepatide [3]
Keep the needle in the vial for the next step
Obesity is a medical condition, plain and simple
Compounded retatrutide typically runs $200 to $500 per month, depending on dose and provider
Published Phase 3 efficacy-estimand data shows retatrutide at 12 mg producing about 28.7% weight loss over 68 weeks (TRIUMPH-4) versus orforglipron at 36 mg producing about 12.4% over 72 weeks (ATTAIN-1)
Backed by a growing network of U.S.-licensed doctors and pharmacists, MEDVi represents a new standard in telehealth weight management one that puts patients, transparency, and outcomes first